Jun 03, 2019 / 12:00PM GMT
Operator
Good morning, and welcome to Moderna's American Society of Clinical Oncology Review Call. (Operator Instructions) Please be advised that the call is being recorded.
At this time, I'd like to turn the call over to Lavina Talukdar, Head, Investor Relations at Moderna. Please proceed.
Lavina Talukdar - Moderna, Inc. - Head of IR
Thank you, operator. Good morning, and welcome to Moderna's ASCO 2019 update call. On today's call, we will review interim data from our Phase I personalized cancer vaccine study that was presented at the American Society of Clinical Oncology meeting over the weekend. You can access the press release issued as well as the studies that we'll be reviewing by going to the investors section of our website at www.modernatx.com.
With me on this call is Stéphane Bancel, Chief Executive Officer; Tal Zaks, Chief Medical Officer; and Lorence Kim, Chief Financial Officer.
Before I begin, I would like to remind everyone that this conference call will include
Moderna, Inc. - Special Call Transcript
Jun 03, 2019
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers